Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 5.6% – Here’s What Happened

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares were down 5.6% during trading on Tuesday . The stock traded as low as $3.18 and last traded at $3.1330. Approximately 174,614 shares traded hands during trading, a decline of 93% from the average daily volume of 2,572,239 shares. The stock had previously closed at $3.32.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, November 17th. Finally, Wells Fargo & Company lifted their price target on shares of Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Ironwood Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $5.34.

Ironwood Pharmaceuticals Stock Down 4.1%

The stock’s 50-day simple moving average is $1.90 and its 200 day simple moving average is $1.21. The firm has a market cap of $517.97 million, a P/E ratio of -63.49 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.15. The firm had revenue of $122.06 million for the quarter, compared to analyst estimates of $74.22 million. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IRWD. Integrated Wealth Concepts LLC grew its holdings in Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,406 shares in the last quarter. McAdam LLC bought a new position in shares of Ironwood Pharmaceuticals during the first quarter valued at approximately $40,000. Vise Technologies Inc. purchased a new position in shares of Ironwood Pharmaceuticals in the 3rd quarter valued at approximately $39,000. BNP Paribas Financial Markets increased its stake in shares of Ironwood Pharmaceuticals by 83.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 15,594 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd bought a new stake in Ironwood Pharmaceuticals in the second quarter worth $25,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.